Tepotinib plus osimertinib in patients with EGFR-mutated NSCLC with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
- Lancet Oncol., Volume 25, Issue 8 , August 2024, Pages 989-1002 | https://doi.org/10.1016/S1470-2045(24)00270-5